(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...
Australia's agriculture sector is poised for a strong year, but the Trump presidency, global conflicts and anti-obesity ...